Table of Contents Table of Contents
Previous Page  7 / 40 Next Page
Show Menu
Previous Page 7 / 40 Next Page
Page Background

With the third grant,

we aim to improve

the heart’s ability to

recover from injury

and regenerate itself,

which we envisage

will become a clinical

reality within the next

10 years.

Being a young discipline in this country,

relative to eye and cancer research, for

example, we have managed to raise

cardiovascular research to greater

heights in Singapore.

What are CVRI’s plans moving


We will continue playing to our

strengths and focus on heart failure.

To tackle a national issue, the cardio-

vascular research community needs

to come together to ght on the same

side. Thus, we wish to next clinch a

S$25 million Open Fund - Large Col-

laborative Grant under National Medi-

cal Research Council working along-

side NHCS, NUHCS, NTU, multiple

A*STAR research institutes and multiple

industry partners. This grant will launch a

major national research initiative address-

ing Singapore’s emerging epidemic of

premature arterial disease from epidemi-

ology and basic vascular biology all the

way through to therapeutic interventions.

This will inevitably overlap with under-

lying problems including diabetes and

high blood pressure. The two domains

of heart failure and arterial disease are

intimately related to one another and

Singapore requires this broadening of

its cardiovascular research focus.•

By Prof. A. Mark Richards Director, Cardiovascular Research Institute (CVRI), NUHCS Prof. Richards has taken up the Directorship of the Cardiovascular Research Institute, Singapore, since October 2010. He leads a group focused on discovery and assay of cardiovascular biomarkers to assess an array of cardiovascular conditions including acute and chronic phases of heart failure, heart valve disease and coronary artery disease.


Changes in a chromosome that affect gene activity and expression.


A measurable indicator of a biological state or condition.